{"entity":{"id":"nct06906562","kind":"trial","name":"A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic","aka":[],"tldr":"A phase 2 trial of pemigatinib in pancreatic cancer, run by Sameek Roychowdhury, now recruiting.","summary":"A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations is a phase 2, interventional study registered as NCT06906562 by Sameek Roychowdhury, with a registry enrolment figure of 40 participants, started 2025-08-26 and due to reach its primary completion in 2026-12-31. Interventions recorded: Pemigatinib; Computed Tomography (CT); Magnetic Resonance Imaging; Optical Coherence Tomography; Bone Scan; Ophthalmoscopy. Conditions listed: Advanced Pancreatic Carcinoma; Metastatic Pancreatic Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8. Primary outcome: Overall Response Rate (ORR). Pancreatic eligibility wording from the registry: \"Patients with histologically or cytologically confirmed advanced or metastatic pancreatic cancer of any histologic classification at the time of diagnosis\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06906562","url":"https://clinicaltrials.gov/study/NCT06906562"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["pemigatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06906562","phase":"2","setting":"A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR2 Gene Fusions or Other FGFR Genetic Alterations","sponsor":"Sameek Roychowdhury","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06906562/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"drug":[{"id":"pemigatinib","kind":"drug","name":"Pemigatinib","route":"/drugs/pemigatinib/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}